WO2002043585A1 - Glucose monitoring instrument having network connectivity - Google Patents

Glucose monitoring instrument having network connectivity Download PDF

Info

Publication number
WO2002043585A1
WO2002043585A1 PCT/US2001/046685 US0146685W WO0243585A1 WO 2002043585 A1 WO2002043585 A1 WO 2002043585A1 US 0146685 W US0146685 W US 0146685W WO 0243585 A1 WO0243585 A1 WO 0243585A1
Authority
WO
WIPO (PCT)
Prior art keywords
glucose
instrument
patient
recited
network
Prior art date
Application number
PCT/US2001/046685
Other languages
French (fr)
Inventor
James R. Braig
Gary E. Hewett
Michael A. Munrow
Julian M. Cortella
Kamrava Azizi
Daniel S. Goldberger
Original Assignee
Optiscan Biomedical Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Optiscan Biomedical Corporation filed Critical Optiscan Biomedical Corporation
Priority to EP01990851A priority Critical patent/EP1339317B1/en
Priority to AU3061702A priority patent/AU3061702A/en
Priority to DE60114228T priority patent/DE60114228T2/en
Priority to CA002429989A priority patent/CA2429989A1/en
Priority to JP2002545571A priority patent/JP3938046B2/en
Priority to AU2002230617A priority patent/AU2002230617B2/en
Publication of WO2002043585A1 publication Critical patent/WO2002043585A1/en
Priority to AU2006200022A priority patent/AU2006200022A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Measuring for diagnostic purposes; Identification of persons
    • A61B5/0002Remote monitoring of patients using telemetry, e.g. transmission of vital signals via a communication network
    • GPHYSICS
    • G16INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16HHEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H40/00ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices
    • G16H40/40ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the management of medical equipment or devices, e.g. scheduling maintenance or upgrades
    • GPHYSICS
    • G16INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16HHEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H40/00ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices
    • G16H40/60ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices
    • G16H40/67ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for remote operation
    • GPHYSICS
    • G16INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16ZINFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS, NOT OTHERWISE PROVIDED FOR
    • G16Z99/00Subject matter not provided for in other main groups of this subclass
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Measuring for diagnostic purposes; Identification of persons
    • A61B5/145Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
    • A61B5/14532Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue for measuring glucose, e.g. by tissue impedance measurement
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S128/00Surgery
    • Y10S128/903Radio telemetry
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S128/00Surgery
    • Y10S128/904Telephone telemetry

Definitions

  • This invention pertains generally to medical equipment for measuring blood glucose levels, and more particularly to a blood glucose measuring instrument having internet-based communication features.
  • a patient having been taught how to use an existing portable glucose monitor is generally required thereafter to independently conduct and record their own measurements. Furthermore, the patient typically is required to both record and assess the measurements without benefit from their practitioner or a supervising authority. Numerous errors can arise from these unsupervised procedures that may result in serious health risks for patients which knowingly, or inadvertently, are not in compliance with medical directives.
  • a glucose monitor typically uses a glucose monitor to be complied with and a notebook in which to record the measurements. Patients often forget, or in some instances forego, conducting and correctly recording their glucose levels as measured by the instrument. If a patient skips a measurement they may even elect to write down a "likely" number in the notebook as if such a measurement had been taken. Patient interaction with such a manual glucose monitoring instrument therefore provides no assurance of correct measurement and recordation. Furthermore, patients in a myriad of situations may require additional information and assistance with regard to the use and maintenance of their glucose measurement instrument. In addition, to assure glucose measurement accuracy, a measuring instrument may require periodic calibration and assuring calibration compliance on instruments in the field is burdensome.
  • the present invention is a glucose monitoring device with remote communications capabilities.
  • a data link is provided between the equipment and a centralized station, or server.
  • the centralized station can monitor important information, such as: equipment calibration, the diligence of a patient taking and recording measurements according to a schedule, and the actual measurements taken by the patient.
  • the centralized station is preferably capable of forwarding information to the patient's physician for evaluation.
  • the centralized station can have optional capability of locking out the patient if the patient has not paid his or her bills.
  • the information is communicated from the glucose monitor directly to the physician.
  • a non-invasive subsurface spectrophotometer instrument equipped with a communications link takes the glucose measurements jand communicates them over a network, such as the internet.
  • the spectrophotometer instrument comprises data communication circuitry, such as dial-up circuitry, and additional session control protocols which integrate a number of the functions within the instrument for communication over a network connection.
  • a destination site, or sites, on the network are configured to receive information from the instrument and to transmit information and services.
  • An object of the invention is to provide a link from patient to practitioner over which timely communication of pertinent glucose monitoring information can travel. Another object of the invention is to provide for remote monitoring of patient compliance.
  • Another object of the invention is to provide for remote equipment monitoring and calibration by a central station.
  • Another object of the invention is to provide for periodic transmission of measurement results.
  • Another object of the invention is to provide network communication over a standardized communications interface.
  • Another object of the invention is to provide a communications structure which can support data encryption.
  • Another object of the invention is to eliminate secretive non-compliance, wherein a patient enters fictional measurement data into the measurement log.
  • Another object of the invention is to engender practical practitioner guidance to patients.
  • Another object of the invention is to allow the instrument manufacturer to track compliance and calibration of the glucose monitoring instrument. Another object of the invention is to provide an accurate database that may be used by insurance and pharmaceutical companies.
  • FIGURE 1 is a functional block diagram showing a glucose monitoring system with network connectivity according to the present invention.
  • FIGURE 2 is a block diagram of the electronic circuits within the glucose monitoring system of FIG. 1.
  • FIGURE 3 is a flowchart exemplifying calibration lockout according to one aspect of the present invention.
  • FIG. 1 through FIG. 3 the present invention is embodied in the system generally shown in FIG. 1 through FIG. 3. It will be appreciated that the system may vary as to configuration and as to details of the parts, and that the method may vary as to the specific steps and sequence, without departing from the basic concepts as disclosed herein.
  • a glucose monitoring system 10 is shown connected to remote stations over a network.
  • the hand of a patient 12 is shown positioned to allow a measurement to be performed by glucose detector element 14 which is capable of taking non-invasive measurements of bodily glucose levels.
  • measurement element 14 comprises a thermal gradient detector such as a spectrophotometer.
  • a signal processing system 16 of the instrument collects the measurements from detector 14 and processes the data into a set of results.
  • the instrument preferably includes input and output devices, such as a display and a set of control inputs (not shown) for communicating information directly to and from the patient.
  • detector 14 and processor 16 form a complete non-invasive glucose measuring device that typically would be used in the home of a patient.
  • Examples of glucose monitoring equipment without internet connectivity are described in U.S. Patent Numbers 5,900,632 to Sterling et al. and 5,615,672 to Braig et al., which are both incorporated herein by reference.
  • the signal processing system is equipped with a network interface along with one or more processing elements for processing the measurement signals and for control of network communications.
  • Measurement data is communicated over the network as determined by the configuration of the system and the state and condition of the measurement being performed. Measurement data may accordingly be communicated to a remote station at the time the measurement is performed, or it may be retained within the instrument and sent to the remote station according to a schedule or other selection criterion.
  • the instrument is capable of comparing each measurement with a set of limits and providing alerts to a supervisory authority regarding excursions therefrom.
  • FIG. 1 the measurement data is shown being routed through a connection 18 to the internet 20, whose destination is routed through connection 22 to a centralized monitoring computer 24, or a server.
  • the centralized computer is preferably capable of checking the data for emergency conditions and logging the data for later use. In addition, the centralized computer may monitor equipment status for proper operation and calibration.
  • the centralized computer may transfer or simultaneously route the data via connection 26 to a computer 28 in the office of a medical practitioner over the internet.
  • the data may be directly sent over the internet to an associated medical practitioner 28 from processor 16.
  • the foregoing data routing is provided as an example, and not as a limitation, of the data routing utilized to provide the internet services as described according to the invention.
  • a panic button is provided as an example, and not as a limitation, of the data routing utilized to provide the internet services as described according to the invention.
  • a panic button is provided as an example, and not as a limitation, of the data routing utilized to provide the internet services as described according to the invention.
  • a panic button is provided as an example, and not as a limitation, of the data routing utilized to provide the internet services as described according to the invention.
  • a panic button is provided as an example, and not as a limitation, of the data routing utilized to provide the internet services as described according to the invention.
  • a panic button is provided as an example, and not as a limitation, of the
  • sound and/or visual output is preferably provided by the instrument for signaling the patient when the time arrives to perform a measurement, or of a directive from a supervisory authority as received over the internet.
  • the present invention provides either a direct or indirect link from the patient to the practitioner.
  • the practitioner is thereby accorded an ability to monitor the status of the patient and may elect to be alerted should deviations in the measurement values or timeliness arise.
  • the system may be configured to transmit measurement data at predetermined intervals, or at the time each measurement is performed.
  • the measurements can be transmitted using various network protocols which include standard internet protocols, encrypted protocols, or email protocols.
  • processor 16 is additionally capable of providing visual or audible cues to the patient when the time arrives to conduct a measurement. These alerts may be augmented by requests, over the internet link of the instrument, from the practitioner. Errors introduced within measurements and recordation within a manual system can thereby be eliminated with the electronically logged measurements. It will be appreciated that the system provides enhanced utility and measurement credibility over the use of an instrument that requires manual logging of the measurements and no practitioner interaction thereof.
  • Secretive non-compliance may also be eliminated as the patient is not conferred the responsibility of manually logging measurements.
  • the measurements collected within the instrument by the patient are capable of being transmitted to the practitioner, or centralized station, such that if a patient is not being diligent in conducting measurements, the practitioner may immediately contact the patient to reinforce the need for compliance.
  • the information provided over the network can be used to warn the practitioner when measurement readings appear abnormal, so that the practitioner may then investigate the situation and verify the status of the patient.
  • the invention has particular utility for patients preferring to receive direct guidance from a practitioner.
  • the information that flows between the patient and the practitioner increases the ability of the practitioner to provide knowledgeable patient guidance.
  • FIG. 2 illustrates the functional blocks of an embodiment of circuitry 32 for implementing the signal processing hardware 16 shown in FIG. 1.
  • a network connection 34 connects to a network processing circuit, exemplified by an Internet Protocol (IP) circuit or processor 36.
  • IP Internet Protocol
  • Numerous circuits are available for providing internet connectivity, such as the SX-StackO chip from Scenix Semiconductor, and the iChipD from Connect One Electronics. These integrated circuit chips and other available chips provide interface layers for supporting a Transmission Control Protocol/Internet Protocol (TCP/IP).
  • the internet protocol chip 36 has an interface 38 with a control processor section 40, which preferably comprises microcontroller or like. Control processor section 40 in turn has access to conventional memory 42.
  • control processor 40 or the internet protocol circuit, to encrypt and provide verification strings or tokens within the data being sent across the network, and accordingly to decrypt information being received and verify the received strings or tokens.
  • the control processor 40 has an interface 44 with the instrumentation circuits 46, which is in turn configured with an interface 48 to the glucose detection element 14 shown in FIG. 1.
  • the network link provides a mechanism to facilitate performing and recording glucose measurements under supervision, while it additionally provides for periodic instrument calibration, and the ability to assure both measurement and calibration compliance.
  • Calibration data can be communicated from instruments in the field to the instrument manufacturer, or a service organization, so that instruments and their calibrations may be logged.
  • the disclosed network link can be utilized to provide various mechanisms for assuring calibration compliance. Generally the mechanisms are of two categories, those that provide information or a warning about calibration, and those that prevent use of an instrument which is out of calibration. Preferably instruments which have exceeded their calibration interval, or schedule, are to be locked out from further use until recalibration is performed. For example, the instrument may be set to operate for thirteen months for a given calibration interval of twelve months.
  • the unit preferably issues warnings prior to the expiration of calibration, and warnings of increased severity after the expiration of the calibration interval. If the unit, however, is not properly calibrated by the end of the thirteen months, normal operation ceases, thereby locking out the user after providing an appropriate error message in regard to the expired calibration. Upon recalibration, the calibrated operation interval is restored to provide for another thirteen month period of calibrated operation.
  • a "lockout command" can be sent to the unit over the communication link from the manufacturer which engages a lockout mode of the device, so that continued operation may not be continued until the unit has been serviced.
  • the lockout command could also be sent in the event that the patient has not paid his or her bills, or be sent under other circumstances warranting lockout of the instrument.
  • Another mode is that of locking out normal instrument use after the expiration of calibration, and allowing limited use thereafter only after a code, or token, has been downloaded from a supervisory site.
  • the code could for instance be provided when a calibration appointment is made for the instrument. To provide continued service and minimize cost, the patient may be allowed to perform calibration checks of the instrument.
  • the patient is supplied with a small set of glucose calibration standards which are read by the instrument once it is put into a calibration mode and preferable connected to a remote site for supervising the process. Should the calibration check pass, wherein the instrument readings fall within normal levels, or be capable of being automatically adjusted thereto, the calibration interval may be extended. Failure of the calibration check would typically necessitate returning the instrument for service.
  • FIG. 3 illustrates an embodiment of a process 50 for assuring calibration compliance within the glucose measurement instrument by utilizing a lockout mechanism.
  • the programmed instructions associated with the glucose measurement instrument are started at block 52 and initialized at block 54, and a check is made on a lockout flag at block 56 to determine if it was set during a prior session by a command received from the internet, or due to being out of calibration.
  • the real-time clock (RTC) of the device is read at block 58 and a calculation is performed at block 60 comparing the current date with the stored calibration date and calibration interval.
  • RTC real-time clock
  • a calculation is performed at block 64 comparing the current date with the stored calibration date and near-calibration interval. Near-calibration is checked at block 66 and, if calibration is to expire soon, then a user warning is issued at block 68, preferably informing the user of the date of the upcoming expiration of the calibration interval.
  • the lockout flag is cleared at block 70 and processing within the glucose measurement instrument continues with normal instrument functions being accessible at block 72, along with calibration and other limited functions at block 74, until the user shuts down the instrument and processing ends at block 76.
  • the calibration procedure itself may be augmented and improved by providing interaction between the servicing party and the manufacturer, such interaction may include providing guidance information to the servicing party, and the collection of measurement information by the manufacturer.
  • the present invention provides functionality beyond that which can be provided by a stand-alone glucose measurement instrument, as the practitioner, or practitioners office, is brought back into the glucose measurement process to confer a portion of the benefits normally associated with an office visit.
  • the features described for the embodiment of a non-invasive glucose monitoring instrument are generally applicable to glucose monitoring hardware in which invasive measurements are taken.
  • the aforesaid description of the invention illustrates how these features provide the capability for two-way data flow which facilitates the conducting and recording of correct measurements while encouraging compliance in regard to both measurements and instrument calibration.
  • the data collected by the system may be utilized by others in addition to the practitioner, such as pharmaceutical companies which may be provided data access to alter or administer medication programs, and " insurance companies which may require data regarding patient diligence according to the specified treatment program.
  • the present invention provides numerous benefits for patients needing to closely monitor blood glucose levels and it can be implemented with numerous variations and alternatives obvious to those skilled in the art.

Abstract

A glucose monitoring instrument having network-based communication features which provide a link between patient and practitioner. The glucose monitoring instrument comprises circuitry for communicating data with one or more destination sites on the network which are configured to transmit and receive information to and from the instrument. Instrument measurements are transmitted over the link in addition to information and guidance, to provide increased accuracy, improved program compliance, and patient guidance from a supervisory authority or medical practitioner. In addition, a set of calibration features encourage calibration compliance.

Description

GLUCOSE MONITORING INSTRUMENT HAVING NETWORK CONNECTIVITY
BACKGROUND OF THE INVENTION
1. Field of the Invention
This invention pertains generally to medical equipment for measuring blood glucose levels, and more particularly to a blood glucose measuring instrument having internet-based communication features.
2. Description of the Background Art
A patient, having been taught how to use an existing portable glucose monitor is generally required thereafter to independently conduct and record their own measurements. Furthermore, the patient typically is required to both record and assess the measurements without benefit from their practitioner or a supervising authority. Numerous errors can arise from these unsupervised procedures that may result in serious health risks for patients which knowingly, or inadvertently, are not in compliance with medical directives.
Typically, patients using a glucose monitor are given a schedule of measurements to be complied with and a notebook in which to record the measurements. Patients often forget, or in some instances forego, conducting and correctly recording their glucose levels as measured by the instrument. If a patient skips a measurement they may even elect to write down a "likely" number in the notebook as if such a measurement had been taken. Patient interaction with such a manual glucose monitoring instrument therefore provides no assurance of correct measurement and recordation. Furthermore, patients in a myriad of situations may require additional information and assistance with regard to the use and maintenance of their glucose measurement instrument. In addition, to assure glucose measurement accuracy, a measuring instrument may require periodic calibration and assuring calibration compliance on instruments in the field is burdensome.
Therefore, a need exists for a glucose monitoring system that provides a link between the patient and the practitioner to encourage compliance and facilitate equipment calibration. The present invention satisfies those needs, as well as others, and overcomes deficiencies incurrent monitoring systems and procedures. BRIEF SUMMARY OF THE INVENTION
The present invention is a glucose monitoring device with remote communications capabilities. According to an aspect of the invention, a data link is provided between the equipment and a centralized station, or server. The centralized station can monitor important information, such as: equipment calibration, the diligence of a patient taking and recording measurements according to a schedule, and the actual measurements taken by the patient. The centralized station is preferably capable of forwarding information to the patient's physician for evaluation. In addition, the centralized station can have optional capability of locking out the patient if the patient has not paid his or her bills. According to another aspect of the invention, the information is communicated from the glucose monitor directly to the physician. As can be seen, therefore, the invention links the monitoring activities performed by the patient and the assessment of those activities by the physician while reducing the chance of human error introduced into the long-term monitoring and treatment process. By way of example, and not of limitation, a non-invasive subsurface spectrophotometer instrument equipped with a communications link according to the invention takes the glucose measurements jand communicates them over a network, such as the internet. The spectrophotometer instrument comprises data communication circuitry, such as dial-up circuitry, and additional session control protocols which integrate a number of the functions within the instrument for communication over a network connection. A destination site, or sites, on the network are configured to receive information from the instrument and to transmit information and services.
An object of the invention is to provide a link from patient to practitioner over which timely communication of pertinent glucose monitoring information can travel. Another object of the invention is to provide for remote monitoring of patient compliance.
Another object of the invention is to provide for remote equipment monitoring and calibration by a central station.
Another object of the invention is to provide for periodic transmission of measurement results.
Another object of the invention is to provide network communication over a standardized communications interface.
Another object of the invention is to provide a communications structure which can support data encryption.
Another object of the invention is to aid compliance by alerting the patient, by sound or visual cues, when the time arrives to conduct a measurement. Another object of the invention is to reduce human error in conducting and recording measurements.
Another object of the invention is to eliminate secretive non-compliance, wherein a patient enters fictional measurement data into the measurement log.
Another object of the invention is to provide the capability of generating programmed practitioner warnings when measurements fall outside the bounds of a selected range. Another object of the invention is to provide a panic button which allows a concerned patient to alert their practitioner.
Another object of the invention is to engender practical practitioner guidance to patients.
Another object of the invention is to allow the instrument manufacturer to track compliance and calibration of the glucose monitoring instrument. Another object of the invention is to provide an accurate database that may be used by insurance and pharmaceutical companies.
Further objects and advantages of the invention will be brought out in the following portions of the specification, wherein the detailed description is for the purpose of fully disclosing preferred embodiments of the invention without placing limitations thereon. BRIEF DESCRIPTION OF THE DRAWINGS The invention will be more fully understood by reference to the following drawings which are provided for illustrative purposes only:
FIGURE 1 is a functional block diagram showing a glucose monitoring system with network connectivity according to the present invention.
FIGURE 2 is a block diagram of the electronic circuits within the glucose monitoring system of FIG. 1. FIGURE 3 is a flowchart exemplifying calibration lockout according to one aspect of the present invention.
DETAILED DESCRIPTION OF THE INVENTION Referring more specifically to the drawings for illustrative purposes, the present invention is embodied in the system generally shown in FIG. 1 through FIG. 3. It will be appreciated that the system may vary as to configuration and as to details of the parts, and that the method may vary as to the specific steps and sequence, without departing from the basic concepts as disclosed herein.
Referring to FIG. 1, a glucose monitoring system 10 is shown connected to remote stations over a network. The hand of a patient 12 is shown positioned to allow a measurement to be performed by glucose detector element 14 which is capable of taking non-invasive measurements of bodily glucose levels. Preferably, measurement element 14 comprises a thermal gradient detector such as a spectrophotometer. A signal processing system 16 of the instrument collects the measurements from detector 14 and processes the data into a set of results. It will be appreciated that the instrument preferably includes input and output devices, such as a display and a set of control inputs (not shown) for communicating information directly to and from the patient.
The combination of detector 14 and processor 16 form a complete non-invasive glucose measuring device that typically would be used in the home of a patient. Examples of glucose monitoring equipment without internet connectivity are described in U.S. Patent Numbers 5,900,632 to Sterling et al. and 5,615,672 to Braig et al., which are both incorporated herein by reference. In accordance with the present invention, however, the signal processing system is equipped with a network interface along with one or more processing elements for processing the measurement signals and for control of network communications.
Data is communicated over the network as determined by the configuration of the system and the state and condition of the measurement being performed. Measurement data may accordingly be communicated to a remote station at the time the measurement is performed, or it may be retained within the instrument and sent to the remote station according to a schedule or other selection criterion. The instrument is capable of comparing each measurement with a set of limits and providing alerts to a supervisory authority regarding excursions therefrom. In FIG. 1 the measurement data is shown being routed through a connection 18 to the internet 20, whose destination is routed through connection 22 to a centralized monitoring computer 24, or a server. The centralized computer is preferably capable of checking the data for emergency conditions and logging the data for later use. In addition, the centralized computer may monitor equipment status for proper operation and calibration. It will be appreciated that multiple servers, or centralized stations, can be provided for communicating with the blood glucose instruments. Furthermore, the centralized computer may transfer or simultaneously route the data via connection 26 to a computer 28 in the office of a medical practitioner over the internet. Alternatively, the data may be directly sent over the internet to an associated medical practitioner 28 from processor 16. It will be appreciated that the foregoing data routing is provided as an example, and not as a limitation, of the data routing utilized to provide the internet services as described according to the invention. Preferably a panic button
30 provides the patient with a mechanism for alerting a medical practitioner should an important concern arise.
In addition, sound and/or visual output is preferably provided by the instrument for signaling the patient when the time arrives to perform a measurement, or of a directive from a supervisory authority as received over the internet.
The present invention, as described herein, provides either a direct or indirect link from the patient to the practitioner. The practitioner is thereby accorded an ability to monitor the status of the patient and may elect to be alerted should deviations in the measurement values or timeliness arise. The system may be configured to transmit measurement data at predetermined intervals, or at the time each measurement is performed. The measurements can be transmitted using various network protocols which include standard internet protocols, encrypted protocols, or email protocols. In the preferred embodiment of the invention, processor 16 is additionally capable of providing visual or audible cues to the patient when the time arrives to conduct a measurement. These alerts may be augmented by requests, over the internet link of the instrument, from the practitioner. Errors introduced within measurements and recordation within a manual system can thereby be eliminated with the electronically logged measurements. It will be appreciated that the system provides enhanced utility and measurement credibility over the use of an instrument that requires manual logging of the measurements and no practitioner interaction thereof.
Secretive non-compliance may also be eliminated as the patient is not conferred the responsibility of manually logging measurements. In using the instrument according to the present invention, the measurements collected within the instrument by the patient are capable of being transmitted to the practitioner, or centralized station, such that if a patient is not being diligent in conducting measurements, the practitioner may immediately contact the patient to reinforce the need for compliance. In addition, the information provided over the network can be used to warn the practitioner when measurement readings appear abnormal, so that the practitioner may then investigate the situation and verify the status of the patient.
It will be appreciated that the invention has particular utility for patients preferring to receive direct guidance from a practitioner. The information that flows between the patient and the practitioner increases the ability of the practitioner to provide knowledgeable patient guidance.
FIG. 2 illustrates the functional blocks of an embodiment of circuitry 32 for implementing the signal processing hardware 16 shown in FIG. 1. A network connection 34 connects to a network processing circuit, exemplified by an Internet Protocol (IP) circuit or processor 36. Numerous circuits are available for providing internet connectivity, such as the SX-StackO chip from Scenix Semiconductor, and the iChipD from Connect One Electronics. These integrated circuit chips and other available chips provide interface layers for supporting a Transmission Control Protocol/Internet Protocol (TCP/IP). The internet protocol chip 36 has an interface 38 with a control processor section 40, which preferably comprises microcontroller or like. Control processor section 40 in turn has access to conventional memory 42. To provide security and fault tolerance of the instrument it is preferable for the control processor, or the internet protocol circuit, to encrypt and provide verification strings or tokens within the data being sent across the network, and accordingly to decrypt information being received and verify the received strings or tokens. The control processor 40 has an interface 44 with the instrumentation circuits 46, which is in turn configured with an interface 48 to the glucose detection element 14 shown in FIG. 1.
The network link provides a mechanism to facilitate performing and recording glucose measurements under supervision, while it additionally provides for periodic instrument calibration, and the ability to assure both measurement and calibration compliance. Calibration data can be communicated from instruments in the field to the instrument manufacturer, or a service organization, so that instruments and their calibrations may be logged. The disclosed network link can be utilized to provide various mechanisms for assuring calibration compliance. Generally the mechanisms are of two categories, those that provide information or a warning about calibration, and those that prevent use of an instrument which is out of calibration. Preferably instruments which have exceeded their calibration interval, or schedule, are to be locked out from further use until recalibration is performed. For example, the instrument may be set to operate for thirteen months for a given calibration interval of twelve months. The unit preferably issues warnings prior to the expiration of calibration, and warnings of increased severity after the expiration of the calibration interval. If the unit, however, is not properly calibrated by the end of the thirteen months, normal operation ceases, thereby locking out the user after providing an appropriate error message in regard to the expired calibration. Upon recalibration, the calibrated operation interval is restored to provide for another thirteen month period of calibrated operation.
Alternatively, or in addition thereto, a "lockout command" can be sent to the unit over the communication link from the manufacturer which engages a lockout mode of the device, so that continued operation may not be continued until the unit has been serviced. The lockout command could also be sent in the event that the patient has not paid his or her bills, or be sent under other circumstances warranting lockout of the instrument. Another mode is that of locking out normal instrument use after the expiration of calibration, and allowing limited use thereafter only after a code, or token, has been downloaded from a supervisory site. Although many variations are possible, the code could for instance be provided when a calibration appointment is made for the instrument. To provide continued service and minimize cost, the patient may be allowed to perform calibration checks of the instrument. The patient is supplied with a small set of glucose calibration standards which are read by the instrument once it is put into a calibration mode and preferable connected to a remote site for supervising the process. Should the calibration check pass, wherein the instrument readings fall within normal levels, or be capable of being automatically adjusted thereto, the calibration interval may be extended. Failure of the calibration check would typically necessitate returning the instrument for service.
FIG. 3 illustrates an embodiment of a process 50 for assuring calibration compliance within the glucose measurement instrument by utilizing a lockout mechanism. The programmed instructions associated with the glucose measurement instrument are started at block 52 and initialized at block 54, and a check is made on a lockout flag at block 56 to determine if it was set during a prior session by a command received from the internet, or due to being out of calibration. Not having been locked out from a prior session, the real-time clock (RTC) of the device is read at block 58 and a calculation is performed at block 60 comparing the current date with the stored calibration date and calibration interval. If upon checking calibration at block 62 the calibration interval has not yet expired, then a calculation is performed at block 64 comparing the current date with the stored calibration date and near-calibration interval. Near-calibration is checked at block 66 and, if calibration is to expire soon, then a user warning is issued at block 68, preferably informing the user of the date of the upcoming expiration of the calibration interval. The lockout flag is cleared at block 70 and processing within the glucose measurement instrument continues with normal instrument functions being accessible at block 72, along with calibration and other limited functions at block 74, until the user shuts down the instrument and processing ends at block 76. If the lockout flag was set from a prior instrument operation, or the calibration interval was exceeded, then a lockout flag would be set at block 78, and the instrument functionality would thereby be restricted to execution of the calibration procedures and other limited functions at block 78 while the normal instrument functionality would not be accessible. The calibration procedure itself may be augmented and improved by providing interaction between the servicing party and the manufacturer, such interaction may include providing guidance information to the servicing party, and the collection of measurement information by the manufacturer.
It will be appreciated that the present invention provides functionality beyond that which can be provided by a stand-alone glucose measurement instrument, as the practitioner, or practitioners office, is brought back into the glucose measurement process to confer a portion of the benefits normally associated with an office visit. It will be recognized that although not providing equivalent results, the features described for the embodiment of a non-invasive glucose monitoring instrument are generally applicable to glucose monitoring hardware in which invasive measurements are taken. The aforesaid description of the invention illustrates how these features provide the capability for two-way data flow which facilitates the conducting and recording of correct measurements while encouraging compliance in regard to both measurements and instrument calibration. Furthermore, the data collected by the system may be utilized by others in addition to the practitioner, such as pharmaceutical companies which may be provided data access to alter or administer medication programs, and "insurance companies which may require data regarding patient diligence according to the specified treatment program.
Accordingly, it will be seen that the present invention provides numerous benefits for patients needing to closely monitor blood glucose levels and it can be implemented with numerous variations and alternatives obvious to those skilled in the art.
Although the description above contains many specificities, these should not be construed as limiting the scope of the invention but as merely providing illustrations of some of the presently preferred embodiments of this invention. Thus the scope of this invention should be determined by the appended claims and their legal equivalents. Therefore, it will be appreciated that the scope of the present invention fully encompasses other embodiments which may become obvious to those skilled in the art, and that the scope of the present invention is accordingly to be limited by nothing other than the appended claims, in which reference to an element in the singular is not intended to mean "one and only one" unless explicitly so stated, but rather "one or more." All structural, chemical, and functional equivalents to the elements of the above-described preferred embodiment that are known to those of ordinary skill in the art are expressly incorporated herein by reference and are intended to be encompassed by the present claims. Moreover, it is not necessary for a device or method to address each and every problem sought to be solved by the present invention, for it to be encompassed by the present claims. Furthermore, no element, component, or method step in the present disclosure is intended to be dedicated to the public regardless of whether the element, component, or method step is explicitly recited in the claims. No claim element herein is to be construed under the provisions of 35 U.S.C. 112, sixth paragraph, unless the element is expressly recited using the phrase "means for."

Claims

WHAT IS CLAIMED IS:
1. In a glucose monitoring instrument having a glucose detection element and signal processing circuitry, the improvement comprising:
(a) means for providing network connectivity of the instrument for the communication of measurements and information between a patient and a supervisory authority, such as a medical practitioner; and
(b) network protocol associated with said instrument capable of providing said network connectivity.
2. A glucose monitoring instrument, comprising:
(a) means for collecting glucose readings from a patient; and
(b) means for communicating said glucose readings over a network to a remote station to allow a supervisory authority, such as a medical practitioner, to oversee data collection and patient treatment.
3. In a glucose measurement instrument having means for measuring patient glucose information and processing that information into one or more readings, the improvement comprising:
(a) a network communications interface capable of communicating over a connected network; and
(b) a controller configured for executing a series of programmed instructions which provide for the communication of measurements and information with a remote station to allow a supervisory authority, such as a medical practitioner, to oversee patient data collection and compliance with a treatment program.
4. In a glucose measurement instrument as recited in claim 3, the improvement further comprising communication of measurement data and time of measurement.
5. In a glucose measurement instrument as recited in claim 3, the improvement further comprising means for communicating a patient initiated alert to said remote station to allow for practitioner intervention on behalf of said patient.
6. In a glucose measurement instrument as recited in claim 4, the improvement further comprising means for communicating calibration information to a remote station to encourage calibration compliance.
7. An apparatus for monitoring the glucose levels of a patient comprising: (a) a glucose detector element capable of taking measurements of bodily glucose levels;
(b) a network communications interface; and
(c) a processor operating from programmed instructions capable of controlling measurements from the glucose detector element and of communicating glucose measurement information via the network communications interface to a remote location.
8. An apparatus as recited in claim 7, wherein the glucose measurement information comprises measurement data, and time of measurement.
9. An apparatus as recited in claim 7, further comprising means for communicating a patient initiated alert to said remote location to allow for practitioner intervention on behalf of said patient.
10. An apparatus as recited in claim 7, further comprising means for communicating calibration information to a remote station for monitoring and controlling aspects of instrument calibration to encourage calibration compliance.
11. An apparatus as recited in claim 7, wherein the glucose detector performs non-invasive blood glucose measurements.
12. An apparatus as recited in claim 7, wherein the glucose detector element comprises a thermal gradient spectrophotometer.
13. An apparatus as recited in claim 7, further comprising programmed instructions for the processor to generate alerts to inform the patient when the time arrives for taking a measurement according to a predetermined schedule or network communicated practitioner directive.
14. An apparatus as recited in claim 7, further comprising programmed instructions for the processor to generate warnings transmitted to a remote location when measured glucose levels exceed the bounds of a preselected range.
15. An apparatus as recited in claim 7, further comprising a panic button which upon activation sends an alert to a remote location over the network communication interface to alert a supervisory authority so that intercession on the patients behalf may be instituted.
16. An apparatus as recited in claim 7, wherein periodic maintenance and calibration information is communicated over the network communication interface to a remote location.
17. An apparatus as recited in claim 16, further comprising a lockout mode that is entered upon receiving commands over the network communication interface, the lockout mode restricting the functionality of the instrument which may be accessed by the user.
18. An apparatus as recited in claim 16, further comprising a lockout mode that is entered upon determining that the calibration interval for the instrument has been exceeded, the lockout mode restricting which functions of the instrument which may currently accessed by the user.
19. A method of providing supervision of blood glucose measurements, comprising the steps of:
(a) collecting a glucose measurement on a portable blood glucose instrument;
(b) processing the glucose measurement into a set of data values; and (c) communicating said data values over a network to a remote station such that a supervisory authority, such as a medical practitioner, may oversee the data collection and patient treatment program, the communication of said data values being provided by a network communications interface within said blood glucose instrument.
PCT/US2001/046685 2000-12-01 2001-11-30 Glucose monitoring instrument having network connectivity WO2002043585A1 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
EP01990851A EP1339317B1 (en) 2000-12-01 2001-11-30 Glucose monitoring instrument having network connectivity
AU3061702A AU3061702A (en) 2000-12-01 2001-11-30 Glucose monitoring instrument having network connectivity
DE60114228T DE60114228T2 (en) 2000-12-01 2001-11-30 GLUCOSE MONITORING DEVICE WITH NETWORK CONNECTION
CA002429989A CA2429989A1 (en) 2000-12-01 2001-11-30 Glucose monitoring instrument having network connectivity
JP2002545571A JP3938046B2 (en) 2000-12-01 2001-11-30 Glucose monitoring device with network connection
AU2002230617A AU2002230617B2 (en) 2000-12-01 2001-11-30 Glucose monitoring instrument having network connectivity
AU2006200022A AU2006200022A1 (en) 2000-12-01 2006-01-05 Glucose monitoring instrument having network connectivity

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/728,743 US6645142B2 (en) 2000-12-01 2000-12-01 Glucose monitoring instrument having network connectivity
US09/728,743 2000-12-01

Publications (1)

Publication Number Publication Date
WO2002043585A1 true WO2002043585A1 (en) 2002-06-06

Family

ID=24928109

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/046685 WO2002043585A1 (en) 2000-12-01 2001-11-30 Glucose monitoring instrument having network connectivity

Country Status (7)

Country Link
US (1) US6645142B2 (en)
EP (1) EP1339317B1 (en)
JP (1) JP3938046B2 (en)
AU (2) AU2002230617B2 (en)
CA (1) CA2429989A1 (en)
DE (1) DE60114228T2 (en)
WO (1) WO2002043585A1 (en)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005230522A (en) * 2004-02-19 2005-09-02 Nuskin Internatl Inc Device and method for biophotonic feedback controlling
US8116842B2 (en) 2004-06-10 2012-02-14 Nse Products, Inc. Bio-photonic feedback control software and database
US8117044B2 (en) 2003-02-20 2012-02-14 Nse Products, Inc. Bio-photonic feedback control software and database
EP2335584B1 (en) 2004-07-13 2015-06-17 DexCom, Inc. Transcutaneous analyte sensor
US9603557B2 (en) 2004-07-13 2017-03-28 Dexcom, Inc. Transcutaneous analyte sensor
US9833143B2 (en) 2004-05-03 2017-12-05 Dexcom, Inc. Transcutaneous analyte sensor
US9986942B2 (en) 2004-07-13 2018-06-05 Dexcom, Inc. Analyte sensor
US10314525B2 (en) 2004-07-13 2019-06-11 Dexcom, Inc. Analyte sensor
US10610136B2 (en) 2005-03-10 2020-04-07 Dexcom, Inc. System and methods for processing analyte sensor data for sensor calibration

Families Citing this family (194)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6036924A (en) 1997-12-04 2000-03-14 Hewlett-Packard Company Cassette of lancet cartridges for sampling blood
US6391005B1 (en) 1998-03-30 2002-05-21 Agilent Technologies, Inc. Apparatus and method for penetration with shaft having a sensor for sensing penetration depth
US8688188B2 (en) 1998-04-30 2014-04-01 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8974386B2 (en) 1998-04-30 2015-03-10 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8480580B2 (en) 1998-04-30 2013-07-09 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US9066695B2 (en) 1998-04-30 2015-06-30 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8346337B2 (en) 1998-04-30 2013-01-01 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US6949816B2 (en) 2003-04-21 2005-09-27 Motorola, Inc. Semiconductor component having first surface area for electrically coupling to a semiconductor chip and second surface area for electrically coupling to a substrate, and method of manufacturing same
US6175752B1 (en) 1998-04-30 2001-01-16 Therasense, Inc. Analyte monitoring device and methods of use
US8465425B2 (en) 1998-04-30 2013-06-18 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
CA2404262C (en) * 2000-03-29 2009-03-24 University Of Virginia Patent Foundation Method, system, and computer program product for the evaluation of glycemic control in diabetes from self-monitoring data
US8641644B2 (en) 2000-11-21 2014-02-04 Sanofi-Aventis Deutschland Gmbh Blood testing apparatus having a rotatable cartridge with multiple lancing elements and testing means
DE60115707T2 (en) * 2000-12-21 2006-08-10 Insulet Corp., Beverly REMOTE CONTROL MEDICAL DEVICE
US6560471B1 (en) 2001-01-02 2003-05-06 Therasense, Inc. Analyte monitoring device and methods of use
EP1397068A2 (en) 2001-04-02 2004-03-17 Therasense, Inc. Blood glucose tracking apparatus and methods
CA2448902C (en) 2001-06-12 2010-09-07 Pelikan Technologies, Inc. Self optimizing lancing device with adaptation means to temporal variations in cutaneous properties
US9795747B2 (en) 2010-06-02 2017-10-24 Sanofi-Aventis Deutschland Gmbh Methods and apparatus for lancet actuation
US7981056B2 (en) 2002-04-19 2011-07-19 Pelikan Technologies, Inc. Methods and apparatus for lancet actuation
DE60234597D1 (en) 2001-06-12 2010-01-14 Pelikan Technologies Inc DEVICE AND METHOD FOR REMOVING BLOOD SAMPLES
US8337419B2 (en) 2002-04-19 2012-12-25 Sanofi-Aventis Deutschland Gmbh Tissue penetration device
US7344507B2 (en) 2002-04-19 2008-03-18 Pelikan Technologies, Inc. Method and apparatus for lancet actuation
US9427532B2 (en) 2001-06-12 2016-08-30 Sanofi-Aventis Deutschland Gmbh Tissue penetration device
US9226699B2 (en) 2002-04-19 2016-01-05 Sanofi-Aventis Deutschland Gmbh Body fluid sampling module with a continuous compression tissue interface surface
US7033371B2 (en) 2001-06-12 2006-04-25 Pelikan Technologies, Inc. Electric lancet actuator
US7749174B2 (en) 2001-06-12 2010-07-06 Pelikan Technologies, Inc. Method and apparatus for lancet launching device intergrated onto a blood-sampling cartridge
US7699791B2 (en) 2001-06-12 2010-04-20 Pelikan Technologies, Inc. Method and apparatus for improving success rate of blood yield from a fingerstick
US7041068B2 (en) 2001-06-12 2006-05-09 Pelikan Technologies, Inc. Sampling module device and method
US7044911B2 (en) * 2001-06-29 2006-05-16 Philometron, Inc. Gateway platform for biological monitoring and delivery of therapeutic compounds
US6781522B2 (en) 2001-08-22 2004-08-24 Kivalo, Inc. Portable storage case for housing a medical monitoring device and an associated method for communicating therewith
US9795334B2 (en) 2002-04-19 2017-10-24 Sanofi-Aventis Deutschland Gmbh Method and apparatus for penetrating tissue
US7547287B2 (en) 2002-04-19 2009-06-16 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
US9314194B2 (en) 2002-04-19 2016-04-19 Sanofi-Aventis Deutschland Gmbh Tissue penetration device
US7297122B2 (en) 2002-04-19 2007-11-20 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
US7232451B2 (en) 2002-04-19 2007-06-19 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
US8702624B2 (en) 2006-09-29 2014-04-22 Sanofi-Aventis Deutschland Gmbh Analyte measurement device with a single shot actuator
US7648468B2 (en) 2002-04-19 2010-01-19 Pelikon Technologies, Inc. Method and apparatus for penetrating tissue
US9248267B2 (en) 2002-04-19 2016-02-02 Sanofi-Aventis Deustchland Gmbh Tissue penetration device
US7229458B2 (en) 2002-04-19 2007-06-12 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
US7892183B2 (en) 2002-04-19 2011-02-22 Pelikan Technologies, Inc. Method and apparatus for body fluid sampling and analyte sensing
US7976476B2 (en) 2002-04-19 2011-07-12 Pelikan Technologies, Inc. Device and method for variable speed lancet
US7717863B2 (en) 2002-04-19 2010-05-18 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
US8221334B2 (en) 2002-04-19 2012-07-17 Sanofi-Aventis Deutschland Gmbh Method and apparatus for penetrating tissue
US7909778B2 (en) 2002-04-19 2011-03-22 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
US7226461B2 (en) 2002-04-19 2007-06-05 Pelikan Technologies, Inc. Method and apparatus for a multi-use body fluid sampling device with sterility barrier release
US7674232B2 (en) 2002-04-19 2010-03-09 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
US8579831B2 (en) 2002-04-19 2013-11-12 Sanofi-Aventis Deutschland Gmbh Method and apparatus for penetrating tissue
US8267870B2 (en) 2002-04-19 2012-09-18 Sanofi-Aventis Deutschland Gmbh Method and apparatus for body fluid sampling with hybrid actuation
US7331931B2 (en) 2002-04-19 2008-02-19 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
US7371247B2 (en) 2002-04-19 2008-05-13 Pelikan Technologies, Inc Method and apparatus for penetrating tissue
US8784335B2 (en) 2002-04-19 2014-07-22 Sanofi-Aventis Deutschland Gmbh Body fluid sampling device with a capacitive sensor
US7491178B2 (en) 2002-04-19 2009-02-17 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
US7901362B2 (en) 2002-04-19 2011-03-08 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
US7291117B2 (en) 2002-04-19 2007-11-06 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
US7727181B2 (en) 2002-10-09 2010-06-01 Abbott Diabetes Care Inc. Fluid delivery device with autocalibration
US7993108B2 (en) 2002-10-09 2011-08-09 Abbott Diabetes Care Inc. Variable volume, shape memory actuated insulin dispensing pump
DE60336834D1 (en) 2002-10-09 2011-06-01 Abbott Diabetes Care Inc FUEL FEEDING DEVICE, SYSTEM AND METHOD
US6931328B2 (en) * 2002-11-08 2005-08-16 Optiscan Biomedical Corp. Analyte detection system with software download capabilities
US8574895B2 (en) 2002-12-30 2013-11-05 Sanofi-Aventis Deutschland Gmbh Method and apparatus using optical techniques to measure analyte levels
AU2003303597A1 (en) 2002-12-31 2004-07-29 Therasense, Inc. Continuous glucose monitoring system and methods of use
US7679407B2 (en) 2003-04-28 2010-03-16 Abbott Diabetes Care Inc. Method and apparatus for providing peak detection circuitry for data communication systems
WO2004107964A2 (en) 2003-06-06 2004-12-16 Pelikan Technologies, Inc. Blood harvesting device with electronic control
US8460243B2 (en) 2003-06-10 2013-06-11 Abbott Diabetes Care Inc. Glucose measuring module and insulin pump combination
US8066639B2 (en) 2003-06-10 2011-11-29 Abbott Diabetes Care Inc. Glucose measuring device for use in personal area network
WO2006001797A1 (en) 2004-06-14 2006-01-05 Pelikan Technologies, Inc. Low pain penetrating
US7722536B2 (en) 2003-07-15 2010-05-25 Abbott Diabetes Care Inc. Glucose measuring device integrated into a holster for a personal area network device
WO2005033659A2 (en) 2003-09-29 2005-04-14 Pelikan Technologies, Inc. Method and apparatus for an improved sample capture device
US9351680B2 (en) 2003-10-14 2016-05-31 Sanofi-Aventis Deutschland Gmbh Method and apparatus for a variable user interface
US7822454B1 (en) 2005-01-03 2010-10-26 Pelikan Technologies, Inc. Fluid sampling device with improved analyte detecting member configuration
EP1706026B1 (en) 2003-12-31 2017-03-01 Sanofi-Aventis Deutschland GmbH Method and apparatus for improving fluidic flow and sample capture
EP1718198A4 (en) 2004-02-17 2008-06-04 Therasense Inc Method and system for providing data communication in continuous glucose monitoring and management system
US7887750B2 (en) * 2004-05-05 2011-02-15 Bayer Healthcare Llc Analytical systems, devices, and cartridges therefor
US8828203B2 (en) 2004-05-20 2014-09-09 Sanofi-Aventis Deutschland Gmbh Printable hydrogels for biosensors
US9820684B2 (en) 2004-06-03 2017-11-21 Sanofi-Aventis Deutschland Gmbh Method and apparatus for a fluid sampling device
CA2572455C (en) 2004-06-04 2014-10-28 Therasense, Inc. Diabetes care host-client architecture and data management system
US8224669B2 (en) * 2004-07-01 2012-07-17 Anchor Holdings, Inc. Chronic disease management system
US7344500B2 (en) 2004-07-27 2008-03-18 Medtronic Minimed, Inc. Sensing system with auxiliary display
IL163796A0 (en) * 2004-08-30 2005-12-18 Gribova Orna A Device for detecting changes in blood glucose level or dardiovacular condition
US8652831B2 (en) 2004-12-30 2014-02-18 Sanofi-Aventis Deutschland Gmbh Method and apparatus for analyte measurement test time
US20070103678A1 (en) * 2005-02-14 2007-05-10 Sterling Bernhard B Analyte detection system with interferent identification and correction
US20070083160A1 (en) * 2005-10-06 2007-04-12 Hall W D System and method for assessing measurements made by a body fluid analyzing device
EP1860993B1 (en) 2005-03-01 2019-01-23 Masimo Laboratories, Inc. Noninvasive multi-parameter patient monitor
CA2601441A1 (en) 2005-03-21 2006-09-28 Abbott Diabetes Care Inc. Method and system for providing integrated medication infusion and analyte monitoring system
US8112240B2 (en) 2005-04-29 2012-02-07 Abbott Diabetes Care Inc. Method and apparatus for providing leak detection in data monitoring and management systems
US7768408B2 (en) 2005-05-17 2010-08-03 Abbott Diabetes Care Inc. Method and system for providing data management in data monitoring system
CN101176099B (en) 2005-05-17 2010-10-13 霍夫曼-拉罗奇有限公司 Host apparatus and method providing calibration and reagent information to a measurement apparatus which makes use of a consumable reagent in a measuring process
US7620437B2 (en) 2005-06-03 2009-11-17 Abbott Diabetes Care Inc. Method and apparatus for providing rechargeable power in data monitoring and management systems
EP1894134A2 (en) * 2005-06-08 2008-03-05 AgaMatrix, Inc. Data collection system and interface
US7756561B2 (en) 2005-09-30 2010-07-13 Abbott Diabetes Care Inc. Method and apparatus for providing rechargeable power in data monitoring and management systems
US7723120B2 (en) * 2005-10-26 2010-05-25 General Electric Company Optical sensor array system and method for parallel processing of chemical and biochemical information
US8133741B2 (en) 2005-10-26 2012-03-13 General Electric Company Methods and systems for delivery of fluidic samples to sensor arrays
US7583190B2 (en) 2005-10-31 2009-09-01 Abbott Diabetes Care Inc. Method and apparatus for providing data communication in data monitoring and management systems
US7766829B2 (en) 2005-11-04 2010-08-03 Abbott Diabetes Care Inc. Method and system for providing basal profile modification in analyte monitoring and management systems
JP5292104B2 (en) * 2006-01-05 2013-09-18 ユニバーシティ オブ バージニア パテント ファウンデーション Computer-implemented method, system, and computer program for evaluating blood glucose variability in diabetes from self-monitoring data
US8344966B2 (en) 2006-01-31 2013-01-01 Abbott Diabetes Care Inc. Method and system for providing a fault tolerant display unit in an electronic device
CA2644620A1 (en) * 2006-03-01 2007-09-07 G.R. Enlightenment Ltd. Apparatus and method for measuring parameters associated with electrochemical processes
US7620438B2 (en) 2006-03-31 2009-11-17 Abbott Diabetes Care Inc. Method and system for powering an electronic device
US8226891B2 (en) 2006-03-31 2012-07-24 Abbott Diabetes Care Inc. Analyte monitoring devices and methods therefor
US20070276197A1 (en) * 2006-05-24 2007-11-29 Lifescan, Inc. Systems and methods for providing individualized disease management
US7920907B2 (en) 2006-06-07 2011-04-05 Abbott Diabetes Care Inc. Analyte monitoring system and method
JP4927082B2 (en) * 2006-06-20 2012-05-09 シャープ株式会社 Setting device, setting system for biometric device, setting method for biometric device, program, and computer-readable recording medium
US8202267B2 (en) 2006-10-10 2012-06-19 Medsolve Technologies, Inc. Method and apparatus for infusing liquid to a body
US8255026B1 (en) 2006-10-12 2012-08-28 Masimo Corporation, Inc. Patient monitor capable of monitoring the quality of attached probes and accessories
US8579853B2 (en) 2006-10-31 2013-11-12 Abbott Diabetes Care Inc. Infusion devices and methods
US20080154513A1 (en) * 2006-12-21 2008-06-26 University Of Virginia Patent Foundation Systems, Methods and Computer Program Codes for Recognition of Patterns of Hyperglycemia and Hypoglycemia, Increased Glucose Variability, and Ineffective Self-Monitoring in Diabetes
US8930203B2 (en) 2007-02-18 2015-01-06 Abbott Diabetes Care Inc. Multi-function analyte test device and methods therefor
US8732188B2 (en) 2007-02-18 2014-05-20 Abbott Diabetes Care Inc. Method and system for providing contextual based medication dosage determination
WO2008103827A1 (en) 2007-02-22 2008-08-28 Welldoc Communications, Inc. System and method for providing treatment recommendations based on models
US10872686B2 (en) 2007-02-22 2020-12-22 WellDoc, Inc. Systems and methods for disease control and management
US10860943B2 (en) 2007-02-22 2020-12-08 WellDoc, Inc. Systems and methods for disease control and management
US8123686B2 (en) 2007-03-01 2012-02-28 Abbott Diabetes Care Inc. Method and apparatus for providing rolling data in communication systems
US8758245B2 (en) * 2007-03-20 2014-06-24 Lifescan, Inc. Systems and methods for pattern recognition in diabetes management
US20080235053A1 (en) * 2007-03-20 2008-09-25 Pinaki Ray Communication medium for diabetes management
US20080234943A1 (en) * 2007-03-20 2008-09-25 Pinaki Ray Computer program for diabetes management
US8374665B2 (en) 2007-04-21 2013-02-12 Cercacor Laboratories, Inc. Tissue profile wellness monitor
US7883898B2 (en) * 2007-05-07 2011-02-08 General Electric Company Method and apparatus for measuring pH of low alkalinity solutions
US7928850B2 (en) 2007-05-08 2011-04-19 Abbott Diabetes Care Inc. Analyte monitoring system and methods
US8461985B2 (en) 2007-05-08 2013-06-11 Abbott Diabetes Care Inc. Analyte monitoring system and methods
US8456301B2 (en) 2007-05-08 2013-06-04 Abbott Diabetes Care Inc. Analyte monitoring system and methods
US8665091B2 (en) 2007-05-08 2014-03-04 Abbott Diabetes Care Inc. Method and device for determining elapsed sensor life
US8597190B2 (en) 2007-05-18 2013-12-03 Optiscan Biomedical Corporation Monitoring systems and methods with fast initialization
US8417311B2 (en) 2008-09-12 2013-04-09 Optiscan Biomedical Corporation Fluid component analysis system and method for glucose monitoring and control
DE102007038801A1 (en) * 2007-08-17 2009-02-19 Biotronik Crm Patent Ag Implantable pressure measuring device and arrangement for internal pressure measurement in a blood vessel
CA3105353A1 (en) 2007-10-10 2009-04-16 Optiscan Biomedical Corporation Fluid component analysis system and method for glucose monitoring and control
WO2009049245A1 (en) * 2007-10-11 2009-04-16 Optiscan Biomedical Corporation Synchronization and configuration of patient monitoring devices
US20090163832A1 (en) * 2007-12-20 2009-06-25 Btnx Inc. Data managing device for a diagnostic instrument
US8633975B2 (en) * 2008-01-16 2014-01-21 Karl Storz Imaging, Inc. Network based endoscopic surgical system
US8708961B2 (en) 2008-01-28 2014-04-29 Medsolve Technologies, Inc. Apparatus for infusing liquid to a body
US20090240127A1 (en) * 2008-03-20 2009-09-24 Lifescan, Inc. Methods of determining pre or post meal time slots or intervals in diabetes management
WO2009126900A1 (en) 2008-04-11 2009-10-15 Pelikan Technologies, Inc. Method and apparatus for analyte detecting device
WO2009131664A2 (en) 2008-04-21 2009-10-29 Carl Frederick Edman Metabolic energy monitoring system
US8799010B2 (en) * 2008-05-07 2014-08-05 Unitedhealth Group Incorporated Telehealth scheduling and communications network
US8523797B2 (en) * 2008-05-08 2013-09-03 Hospira, Inc. Automated point-of-care fluid testing device and method of using the same
US7959598B2 (en) 2008-08-20 2011-06-14 Asante Solutions, Inc. Infusion pump systems and methods
EP2350027A1 (en) * 2008-09-04 2011-08-03 Mitsubishi Tanabe Pharma Corporation Tri-substituted pyrimidine compounds and their use as pde10 inhibitors
US8103456B2 (en) 2009-01-29 2012-01-24 Abbott Diabetes Care Inc. Method and device for early signal attenuation detection using blood glucose measurements
US8560082B2 (en) 2009-01-30 2013-10-15 Abbott Diabetes Care Inc. Computerized determination of insulin pump therapy parameters using real time and retrospective data processing
US9375169B2 (en) 2009-01-30 2016-06-28 Sanofi-Aventis Deutschland Gmbh Cam drive for managing disposable penetrating member actions with a single motor and motor and control system
WO2010129375A1 (en) 2009-04-28 2010-11-11 Abbott Diabetes Care Inc. Closed loop blood glucose control algorithm analysis
US9226701B2 (en) 2009-04-28 2016-01-05 Abbott Diabetes Care Inc. Error detection in critical repeating data in a wireless sensor system
WO2010138856A1 (en) 2009-05-29 2010-12-02 Abbott Diabetes Care Inc. Medical device antenna systems having external antenna configurations
EP2456351B1 (en) 2009-07-23 2016-10-12 Abbott Diabetes Care, Inc. Real time management of data relating to physiological control of glucose levels
WO2011026147A1 (en) 2009-08-31 2011-03-03 Abbott Diabetes Care Inc. Analyte signal processing device and methods
WO2011026148A1 (en) 2009-08-31 2011-03-03 Abbott Diabetes Care Inc. Analyte monitoring system and methods for managing power and noise
US9320461B2 (en) 2009-09-29 2016-04-26 Abbott Diabetes Care Inc. Method and apparatus for providing notification function in analyte monitoring systems
US9839381B1 (en) 2009-11-24 2017-12-12 Cercacor Laboratories, Inc. Physiological measurement system with automatic wavelength adjustment
GB2487882B (en) 2009-12-04 2017-03-29 Masimo Corp Calibration for multi-stage physiological monitors
WO2011112972A2 (en) 2010-03-11 2011-09-15 Philometron, Inc. Physiological monitor system for determining medication delivery and outcome
US8965476B2 (en) 2010-04-16 2015-02-24 Sanofi-Aventis Deutschland Gmbh Tissue penetration device
US9138180B1 (en) 2010-05-03 2015-09-22 Masimo Corporation Sensor adapter cable
US10136845B2 (en) 2011-02-28 2018-11-27 Abbott Diabetes Care Inc. Devices, systems, and methods associated with analyte monitoring devices and devices incorporating the same
US9626650B2 (en) 2011-04-14 2017-04-18 Elwha Llc Cost-effective resource apportionment technologies suitable for facilitating therapies
US10445846B2 (en) 2011-04-14 2019-10-15 Elwha Llc Cost-effective resource apportionment technologies suitable for facilitating therapies
US8599009B2 (en) 2011-08-16 2013-12-03 Elwha Llc Systematic distillation of status data relating to regimen compliance
JP6443802B2 (en) 2011-11-07 2018-12-26 アボット ダイアベティス ケア インコーポレイテッドAbbott Diabetes Care Inc. Analyte monitoring apparatus and method
US9968306B2 (en) 2012-09-17 2018-05-15 Abbott Diabetes Care Inc. Methods and apparatuses for providing adverse condition notification with enhanced wireless communication range in analyte monitoring systems
KR102037416B1 (en) 2012-12-17 2019-10-28 삼성전자주식회사 Method for managing of external devices, method for operating of an external device, host device, management server, and the external device
US9585563B2 (en) 2012-12-31 2017-03-07 Dexcom, Inc. Remote monitoring of analyte measurements
US9730621B2 (en) 2012-12-31 2017-08-15 Dexcom, Inc. Remote monitoring of analyte measurements
US9351670B2 (en) 2012-12-31 2016-05-31 Abbott Diabetes Care Inc. Glycemic risk determination based on variability of glucose levels
US10383580B2 (en) 2012-12-31 2019-08-20 Abbott Diabetes Care Inc. Analysis of glucose median, variability, and hypoglycemia risk for therapy guidance
US10404784B2 (en) * 2013-02-22 2019-09-03 Samsung Electronics Co., Ltd. Method and system for transmitting result of examination of specimen from medical device to destination
EP2770452A1 (en) * 2013-02-22 2014-08-27 Samsung Electronics Co., Ltd. Method and system for transmitting result of examination of specimen from medical device to destination through mobile device
CN105122254B (en) * 2013-03-15 2019-03-15 雅培医护站股份有限公司 Management method and system for point-of care test
WO2014145335A1 (en) 2013-03-15 2014-09-18 Abbott Diabetes Care Inc. System and method to manage diabetes based on glucose median, glucose variability, and hypoglycemic risk
US20150133861A1 (en) 2013-11-11 2015-05-14 Kevin P. McLennan Thermal management system and method for medical devices
GB2523989B (en) 2014-01-30 2020-07-29 Insulet Netherlands B V Therapeutic product delivery system and method of pairing
US10143795B2 (en) 2014-08-18 2018-12-04 Icu Medical, Inc. Intravenous pole integrated power, control, and communication system and method for an infusion pump
CN111905188B (en) 2015-02-18 2022-07-22 英赛罗公司 Fluid delivery and infusion device and method of use
WO2016189419A1 (en) 2015-05-26 2016-12-01 Hospira, Nc. Disposable infusion fluid delivery device for programmable large volume drug delivery
KR102443262B1 (en) 2015-09-23 2022-09-13 삼성전자주식회사 Method and apparatus for predicting analyte concentration
WO2017091624A1 (en) 2015-11-24 2017-06-01 Insulet Corporation Wearable automated medication delivery system
EP3397140A4 (en) 2015-12-28 2019-08-21 Dexcom, Inc. Systems and methods for remote and host monitoring communications
US10327680B2 (en) 2015-12-28 2019-06-25 Medtronic Minimed, Inc. Sensor systems, devices, and methods for continuous glucose monitoring
US10327686B2 (en) * 2015-12-28 2019-06-25 Medtronic Minimed, Inc. Sensor systems, devices, and methods for continuous glucose monitoring
US20170181672A1 (en) 2015-12-28 2017-06-29 Medtronic Minimed, Inc. Sensor systems, devices, and methods for continuous glucose monitoring
EP3374905A1 (en) 2016-01-13 2018-09-19 Bigfoot Biomedical, Inc. User interface for diabetes management system
CN112933333B (en) 2016-01-14 2023-03-28 比格福特生物医药公司 Adjusting insulin delivery rate
WO2018058041A1 (en) 2016-09-23 2018-03-29 Insulet Corporation Fluid delivery device with sensor
USD928199S1 (en) 2018-04-02 2021-08-17 Bigfoot Biomedical, Inc. Medication delivery device with icons
CA3099113A1 (en) 2018-05-04 2019-11-07 Insulet Corporation Safety constraints for a control algorithm-based drug delivery system
CN112789070A (en) 2018-09-28 2021-05-11 英赛罗公司 Mode of activity of the artificial pancreas System
US11565039B2 (en) 2018-10-11 2023-01-31 Insulet Corporation Event detection for drug delivery system
USD939079S1 (en) 2019-08-22 2021-12-21 Icu Medical, Inc. Infusion pump
US11801344B2 (en) 2019-09-13 2023-10-31 Insulet Corporation Blood glucose rate of change modulation of meal and correction insulin bolus quantity
US11935637B2 (en) 2019-09-27 2024-03-19 Insulet Corporation Onboarding and total daily insulin adaptivity
US11833329B2 (en) 2019-12-20 2023-12-05 Insulet Corporation Techniques for improved automatic drug delivery performance using delivery tendencies from past delivery history and use patterns
US11551802B2 (en) 2020-02-11 2023-01-10 Insulet Corporation Early meal detection and calorie intake detection
US11547800B2 (en) 2020-02-12 2023-01-10 Insulet Corporation User parameter dependent cost function for personalized reduction of hypoglycemia and/or hyperglycemia in a closed loop artificial pancreas system
US11324889B2 (en) 2020-02-14 2022-05-10 Insulet Corporation Compensation for missing readings from a glucose monitor in an automated insulin delivery system
US11607493B2 (en) 2020-04-06 2023-03-21 Insulet Corporation Initial total daily insulin setting for user onboarding
US11684716B2 (en) 2020-07-31 2023-06-27 Insulet Corporation Techniques to reduce risk of occlusions in drug delivery systems
US11904140B2 (en) 2021-03-10 2024-02-20 Insulet Corporation Adaptable asymmetric medicament cost component in a control system for medicament delivery
US11738144B2 (en) 2021-09-27 2023-08-29 Insulet Corporation Techniques enabling adaptation of parameters in aid systems by user input
US11439754B1 (en) 2021-12-01 2022-09-13 Insulet Corporation Optimizing embedded formulations for drug delivery

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5615672A (en) 1993-01-28 1997-04-01 Optiscan, Inc. Self-emission noninvasive infrared spectrophotometer with body temperature compensation
US5900632A (en) 1997-03-12 1999-05-04 Optiscan Biomedical Corporation Subsurface thermal gradient spectrometry
WO1999025110A1 (en) * 1997-11-12 1999-05-20 I-Flow Corporation Method and apparatus for monitoring a patient
EP0970655A1 (en) * 1997-01-20 2000-01-12 Carpe Diem Comercial Sanitaria Apparatus and system for the telematic control of physiological parameters of patients
WO2000028460A2 (en) * 1998-11-09 2000-05-18 Lifestream Technologies, Inc. Diagnostic device for health monitoring and network-based health assessment system and medical record maintenance system
WO2000032258A1 (en) * 1998-11-30 2000-06-08 Novo Nordisk A/S A method and a system for assisting a user in a medical self treatment, said self treatment comprising a plurality of actions
WO2000053085A1 (en) * 1999-03-10 2000-09-14 Optiscan Biomedical Corporation Solid-state non-invasive absorption spectrometer

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0290683A3 (en) * 1987-05-01 1988-12-14 Diva Medical Systems B.V. Diabetes management system and apparatus
US5956501A (en) * 1997-01-10 1999-09-21 Health Hero Network, Inc. Disease simulation system and method
JP3873092B2 (en) * 1997-03-10 2007-01-24 アークレイ株式会社 Distributed inspection and measurement system
US5966654A (en) * 1996-11-01 1999-10-12 Ericsson Inc. Recyclable cellular telephone and method and apparatus for supporting the use of a recyclable cellular telephone within a cellular telephone network acting as a theme park communicator/scheduler
FI107080B (en) * 1997-10-27 2001-05-31 Nokia Mobile Phones Ltd measuring device
US5967975A (en) * 1997-11-13 1999-10-19 Ridgeway; Donald G. Home health parameter monitoring system
US6248067B1 (en) * 1999-02-05 2001-06-19 Minimed Inc. Analyte sensor and holter-type monitor system and method of using the same
CN1329471A (en) * 1998-11-30 2002-01-02 诺沃挪第克公司 Medical system and control method for assisting user in medical self treatment using said-system
CA2351398A1 (en) 1998-11-30 2000-06-08 Abbott Laboratories Analyte test instrument having improved calibration and communication processes
CA2365609A1 (en) * 1999-02-12 2000-08-17 Cygnus, Inc. Devices and methods for frequent measurement of an analyte present in a biological system
JP2000275207A (en) * 1999-03-24 2000-10-06 Olympus Optical Co Ltd Clinical electrolyte measuring method
DE60126448T2 (en) 2000-04-17 2007-06-14 Nec Corp. Method and system for providing a home-based health service
US6413213B1 (en) 2000-04-18 2002-07-02 Roche Diagnostics Corporation Subscription based monitoring system and method

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5615672A (en) 1993-01-28 1997-04-01 Optiscan, Inc. Self-emission noninvasive infrared spectrophotometer with body temperature compensation
EP0970655A1 (en) * 1997-01-20 2000-01-12 Carpe Diem Comercial Sanitaria Apparatus and system for the telematic control of physiological parameters of patients
US5900632A (en) 1997-03-12 1999-05-04 Optiscan Biomedical Corporation Subsurface thermal gradient spectrometry
WO1999025110A1 (en) * 1997-11-12 1999-05-20 I-Flow Corporation Method and apparatus for monitoring a patient
WO2000028460A2 (en) * 1998-11-09 2000-05-18 Lifestream Technologies, Inc. Diagnostic device for health monitoring and network-based health assessment system and medical record maintenance system
WO2000032258A1 (en) * 1998-11-30 2000-06-08 Novo Nordisk A/S A method and a system for assisting a user in a medical self treatment, said self treatment comprising a plurality of actions
WO2000053085A1 (en) * 1999-03-10 2000-09-14 Optiscan Biomedical Corporation Solid-state non-invasive absorption spectrometer

Cited By (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8117044B2 (en) 2003-02-20 2012-02-14 Nse Products, Inc. Bio-photonic feedback control software and database
JP4568578B2 (en) * 2004-02-19 2010-10-27 ニュースキン インターナショナル インコーポレイテッド Biophotonic feedback control apparatus and method
JP2005230522A (en) * 2004-02-19 2005-09-02 Nuskin Internatl Inc Device and method for biophotonic feedback controlling
US9833143B2 (en) 2004-05-03 2017-12-05 Dexcom, Inc. Transcutaneous analyte sensor
US10327638B2 (en) 2004-05-03 2019-06-25 Dexcom, Inc. Transcutaneous analyte sensor
US8116842B2 (en) 2004-06-10 2012-02-14 Nse Products, Inc. Bio-photonic feedback control software and database
US11883164B2 (en) 2004-07-13 2024-01-30 Dexcom, Inc. System and methods for processing analyte sensor data for sensor calibration
US11026605B1 (en) 2004-07-13 2021-06-08 Dexcom, Inc. Analyte sensor
US9814414B2 (en) 2004-07-13 2017-11-14 Dexcom, Inc. Transcutaneous analyte sensor
US9610031B2 (en) 2004-07-13 2017-04-04 Dexcom, Inc. Transcutaneous analyte sensor
US9833176B2 (en) 2004-07-13 2017-12-05 Dexcom, Inc. Transcutaneous analyte sensor
US9986942B2 (en) 2004-07-13 2018-06-05 Dexcom, Inc. Analyte sensor
US10022078B2 (en) 2004-07-13 2018-07-17 Dexcom, Inc. Analyte sensor
US10314525B2 (en) 2004-07-13 2019-06-11 Dexcom, Inc. Analyte sensor
US9603557B2 (en) 2004-07-13 2017-03-28 Dexcom, Inc. Transcutaneous analyte sensor
US10524703B2 (en) 2004-07-13 2020-01-07 Dexcom, Inc. Transcutaneous analyte sensor
US10918313B2 (en) 2004-07-13 2021-02-16 Dexcom, Inc. Analyte sensor
US11064917B2 (en) 2004-07-13 2021-07-20 Dexcom, Inc. Analyte sensor
US11045120B2 (en) 2004-07-13 2021-06-29 Dexcom, Inc. Analyte sensor
US9801572B2 (en) 2004-07-13 2017-10-31 Dexcom, Inc. Transcutaneous analyte sensor
US10709363B2 (en) 2004-07-13 2020-07-14 Dexcom, Inc. Analyte sensor
US10709362B2 (en) 2004-07-13 2020-07-14 Dexcom, Inc. Analyte sensor
US10993641B2 (en) 2004-07-13 2021-05-04 Dexcom, Inc. Analyte sensor
EP2335584B1 (en) 2004-07-13 2015-06-17 DexCom, Inc. Transcutaneous analyte sensor
US10722152B2 (en) 2004-07-13 2020-07-28 Dexcom, Inc. Analyte sensor
US10993642B2 (en) 2004-07-13 2021-05-04 Dexcom, Inc. Analyte sensor
US10799159B2 (en) 2004-07-13 2020-10-13 Dexcom, Inc. Analyte sensor
US10799158B2 (en) 2004-07-13 2020-10-13 Dexcom, Inc. Analyte sensor
US10980452B2 (en) 2004-07-13 2021-04-20 Dexcom, Inc. Analyte sensor
US10813576B2 (en) 2004-07-13 2020-10-27 Dexcom, Inc. Analyte sensor
US10827956B2 (en) 2004-07-13 2020-11-10 Dexcom, Inc. Analyte sensor
US10932700B2 (en) 2004-07-13 2021-03-02 Dexcom, Inc. Analyte sensor
US10918315B2 (en) 2004-07-13 2021-02-16 Dexcom, Inc. Analyte sensor
US10918314B2 (en) 2004-07-13 2021-02-16 Dexcom, Inc. Analyte sensor
US10716498B2 (en) 2005-03-10 2020-07-21 Dexcom, Inc. System and methods for processing analyte sensor data for sensor calibration
US11000213B2 (en) 2005-03-10 2021-05-11 Dexcom, Inc. System and methods for processing analyte sensor data for sensor calibration
US10898114B2 (en) 2005-03-10 2021-01-26 Dexcom, Inc. System and methods for processing analyte sensor data for sensor calibration
US10918318B2 (en) 2005-03-10 2021-02-16 Dexcom, Inc. System and methods for processing analyte sensor data for sensor calibration
US10918317B2 (en) 2005-03-10 2021-02-16 Dexcom, Inc. System and methods for processing analyte sensor data for sensor calibration
US10925524B2 (en) 2005-03-10 2021-02-23 Dexcom, Inc. System and methods for processing analyte sensor data for sensor calibration
US10856787B2 (en) 2005-03-10 2020-12-08 Dexcom, Inc. System and methods for processing analyte sensor data for sensor calibration
US10610136B2 (en) 2005-03-10 2020-04-07 Dexcom, Inc. System and methods for processing analyte sensor data for sensor calibration
US10743801B2 (en) 2005-03-10 2020-08-18 Dexcom, Inc. System and methods for processing analyte sensor data for sensor calibration
US10709364B2 (en) 2005-03-10 2020-07-14 Dexcom, Inc. System and methods for processing analyte sensor data for sensor calibration
US10918316B2 (en) 2005-03-10 2021-02-16 Dexcom, Inc. System and methods for processing analyte sensor data for sensor calibration
US10617336B2 (en) 2005-03-10 2020-04-14 Dexcom, Inc. System and methods for processing analyte sensor data for sensor calibration
US10610135B2 (en) 2005-03-10 2020-04-07 Dexcom, Inc. System and methods for processing analyte sensor data for sensor calibration
US11051726B2 (en) 2005-03-10 2021-07-06 Dexcom, Inc. System and methods for processing analyte sensor data for sensor calibration
US10610137B2 (en) 2005-03-10 2020-04-07 Dexcom, Inc. System and methods for processing analyte sensor data for sensor calibration
US10813577B2 (en) 2005-06-21 2020-10-27 Dexcom, Inc. Analyte sensor

Also Published As

Publication number Publication date
DE60114228D1 (en) 2005-11-24
AU3061702A (en) 2002-06-11
US6645142B2 (en) 2003-11-11
EP1339317A1 (en) 2003-09-03
AU2002230617B2 (en) 2005-10-06
JP2004514494A (en) 2004-05-20
DE60114228T2 (en) 2006-07-06
CA2429989A1 (en) 2002-06-06
US20020068858A1 (en) 2002-06-06
EP1339317B1 (en) 2005-10-19
JP3938046B2 (en) 2007-06-27

Similar Documents

Publication Publication Date Title
EP1339317B1 (en) Glucose monitoring instrument having network connectivity
AU2002230617A1 (en) Glucose monitoring instrument having network connectivity
US20200023127A1 (en) Management of infusion data methods and apparatus
JP6014013B2 (en) Wireless medical data communication system and method
CA2514294C (en) Medical data communication notification and messaging system and method
US8234128B2 (en) System and method for verifying medical device operational parameters
US20040176667A1 (en) Method and system for medical device connectivity
US20040167465A1 (en) System and method for medical device authentication
WO2004070556A2 (en) Method and system for integrating data flows
WO2004070562A9 (en) System and method for notification and escalation of medical data alerts
JP2006520037A5 (en)
WO2005010796A2 (en) Wireless medical communication system and method
WO2004070549A2 (en) Separation of validated information and functions in a healthcare system
US20070219830A1 (en) System and method of remote care on-line monitoring
JP2012011204A (en) Wireless medical data communication system and method
AU2006200022A1 (en) Glucose monitoring instrument having network connectivity
JP2002269231A (en) Clinical data analysis processing method, system, computer program and medium
JP2010049698A (en) System and method for verifying operational parameter

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU CA JP

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): DE FR GB IE IT

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2429989

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2002545571

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2001990851

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2002230617

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2001990851

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 2001990851

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 2002230617

Country of ref document: AU